Skip to main content
Premium Trial:

Request an Annual Quote

454 Life Sciences, Roche Diagnostics, Keygene, Cold Spring Harbor Laboratory Press, W.H. Freeman and Company

Premium
454 Life Sciences said this week that it has shipped its new high-throughput Genome Sequencer FLX system to its marketing partner Roche Diagnostics in preparation for a launch later this quarter.
 
According to the CuraGen subsidiary, the GS FLX provides longer reads, higher throughput, and improved accuracy compared to the company’s current Genome Sequencer 20 system.
 
Specifically, 454 said that the GS FLX offers read lengths between 200 and 300 bases; an average of more than 400,000 reads per run; single read accuracy of more than 99.5 percent over 200 bases; and consensus accuracy of greater than 99.99 percent.
 
454 said that it would take less than eight hours for a single instrument to generate around 100 megabases.
 
Existing Genome Sequencer 20 systems can “easily be upgraded on-site” to GS FLX, the company said. Early adopters began receiving the GS FLX for evaluation purposes in November.
 

 
Keygene has launched KeyPoint, a mutation screening technology that combines DNA pooling with high-throughput sequencing, for example on 454’s Genome Sequencer.
 
Keygene said that KeyPoint can pinpoint the exact location of multiple mutations in multiple genes in a mutant population in one sequence run, and that the technology also provides the sequence information required to establish the nature of the identified mutations.
 
Keygene will provide the technology as a service and will present it at the Plant & Animal Genome conference, which will be held in San Diego on Jan. 13-17.
 

 
Cold Spring Harbor Laboratory Press and W.H. Freeman and Company have released the third edition of the textbook Recombinant DNA: Genes and Genomes — A Short Course. The new edition includes “descriptions of genome sequencing technologies, biological insights from sequencing projects, and practical applications of genetics and genomics research,” according to the publishers. 

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.